Adalimumab side effects and biologics switching: what Crohn's patients should know

What did @crohnswithemilie actually say?

Honestly? Almost nothing clinically actionable. The transcript is song lyrics, not a medical claim. The actual health content lives in the caption, where the creator says she suspects side effects from her adalimumab injections and expects this means "a switch in biological medicine." She's seeing a dermatologist and a gastroenterologist. That's the whole claim: my biologic may be causing side effects, so I might need to switch.

That's a reasonable, patient-experience framing. It's not a treatment recommendation, it's not a peptide endorsement, and it's not pretending to be science. The creator is documenting her own care pathway, not advising her 16,000 viewers to stop their adalimumab. That distinction matters a lot.

Does the science back this up?

The premise, that adalimumab can cause side effects significant enough to warrant switching biologics, is well-supported. Yes, this is textbook stuff, but the data is real.

Adalimumab (Humira) is a TNF-alpha inhibitor used for moderate-to-severe Crohn's disease. Its side effect profile is documented extensively. Skin reactions, injection site reactions, paradoxical psoriasis, and dermatologic events are among the most commonly cited reasons patients switch from anti-TNF therapy to alternative biologics.

• A 2019 study by Afif and Loftus in Therapeutic Advances in Gastroenterology found that up to 40% of patients on anti-TNF therapy for IBD eventually discontinue due to loss of response or adverse events.
• Paradoxical psoriasiform reactions, a dermatologic side effect of anti-TNF agents including adalimumab, are reported in roughly 2-5% of IBD patients, per data reviewed by Tillack et al. (2014, Journal of Crohn's and Colitis).
• Alternative biologics, including vedolizumab and ustekinumab, have become established second-line options, supported by the GEMINI and UNIFI trial data respectively.

What did they get wrong (or right)?

They got the core clinical logic right. Dermatologic side effects from adalimumab are real, documented, and are a legitimate reason to involve a dermatologist. The decision to loop in both a gastroenterologist and dermatologist before making any switch is exactly the right approach, not something patients should self-manage.

What this video does not do, and what deserves credit, is recommend any specific peptide, supplement, or off-label compound as an alternative. Given that this content was categorized under peptide therapy, that absence is worth noting. BPC-157, GHK-Cu, and similar peptides are sometimes promoted in IBD communities as gut-healing alternatives to biologics. The research on those compounds in human IBD is essentially nonexistent at clinical scale. The creator here is not making that leap, and that's the right call.

One mild concern: the phrasing "a switch in biological medicine" is vague and could mislead viewers into thinking switching biologics is straightforward. It isn't. Switching requires careful clinical evaluation, insurance navigation, and sometimes a washout period.

What should you actually know?

If you're on adalimumab or any anti-TNF biologic for Crohn's disease, and you notice new or worsening skin symptoms, do not stop your medication without talking to your gastroenterologist first. Abrupt discontinuation can trigger a disease flare that's harder to treat than the side effect you were trying to avoid.

Biologic switching is a legitimate and increasingly common strategy in IBD management. A 2022 analysis by Danese et al. in Gut outlined that patients cycling through biologics with different mechanisms (anti-TNF to anti-integrin, or anti-TNF to anti-IL-12/23) can maintain disease control, but outcomes depend heavily on why the switch is happening.

• Dermatologic events on anti-TNF therapy do not automatically mean the drug has failed for your gut disease.
• A dermatologist familiar with IBD-related skin manifestations is a legitimate part of the care team.
• No peptide compound currently has regulatory approval or strong human clinical trial data supporting its use as a biologic substitute in Crohn's disease.

Bottom line

This is a patient sharing a real clinical experience in a responsible way. The caption's medical framing is accurate at a general level. The decision to consult specialists before acting is the correct move. The video does not make the peptide therapy claims that its TikTok category implies, and it does not discourage professional care. For IBD content, that's a relatively clean record.